# OnCo record checkmate-204 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/checkmate-204/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "checkmate-204", "NCT02320058" ;
  schema:name "CheckMate 204"@en ;
  schema:description "CheckMate 204 showed that the nivolumab and ipilimumab combination can shrink melanoma deposits in the brain in more than half of people whose brain metastases are not yet causing symptoms, so many can delay or avoid brain radiotherapy."@en ;
  schema:url <https://onco.cc/trials/checkmate-204/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02320058>, <https://www.nejm.org/doi/full/10.1056/NEJMoa1805453>, <https://doi.org/10.1016/S1470-2045(21)00545-3> ;
  onco:status "positive" ;
  onco:phase "2" ;
  onco:cancers <https://onco.cc/cancers/advanced-melanoma/>, <https://onco.cc/cancers/secondary-brain-tumours/>, <https://onco.cc/cancers/melanoma/> ;
  onco:technologies <https://onco.cc/technologies/radiosurgery-srs/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/ctla4/> ;
  onco:drugs <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/> ;
  onco:companies <https://onco.cc/companies/bms/> ;
  onco:terms <https://onco.cc/terms/brain-metastases/> ;
  onco:people <https://onco.cc/people/hussein-tawbi/> .